ORCHESTRA BIOMED
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
ORCHESTRA BIOMED
Industry:
Biotechnology Health Care Medical Medical Device
Founded:
2017-01-01
Status:
Active
Contact:
917-254-4900
Total Funding:
282.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Content Delivery Network Google Universal Analytics JsDelivr Cloudflare JS CDN JS BootstrapCDN JQuery CDN
Current Advisors List
Advisor
2018-10-01
Current Employees Featured
David Hochman Chief Executive Officer and Founder @ Orchestra BioMed
Chief Executive Officer and Founder
Darren Sherman President, Chief Operating Officer, Director and Founder @ Orchestra BioMed
President, Chief Operating Officer, Director and Founder
Paul Goode Vice President, Development @ Orchestra BioMed
Vice President, Development
2019-10-01
Eric Fain Director, Board Of Directors @ Orchestra BioMed
Director, Board Of Directors
2018-11-01
Michael Kaswan Chief Financial Officer @ Orchestra BioMed
Chief Financial Officer
2022-01-01
Founder
Investors List
Avenue Venture
Avenue Venture investment in Debt Financing - Orchestra BioMed
Terumo Corporation
Terumo Corporation investment in Series D - Orchestra BioMed
Perceptive Advisors
Perceptive Advisors investment in Series D - Orchestra BioMed
RTW Investments LLC
RTW Investments LLC investment in Series D - Orchestra BioMed
Medtronic
Medtronic investment in Series D - Orchestra BioMed
SternAegis
SternAegis investment in Series D - Orchestra BioMed
Terumo Corporation
Terumo Corporation investment in Corporate Round - Orchestra BioMed
SternAegis
SternAegis investment in Series B - Orchestra BioMed
Soleus Capital
Soleus Capital investment in Series B - Orchestra BioMed
RTW Investments LLC
RTW Investments LLC investment in Series B - Orchestra BioMed
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-05-17 | Vivasure Medical | Orchestra BioMed investment in Series D - Vivasure Medical | 23 M USD |
More informations about "Orchestra BioMed"
Orchestra BioMed - Crunchbase Investor Profile
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for …See details»
Orchestra BioMed | Investor Relations
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Our partnership-enabled business model …See details»
Our People - Orchestra BioMed
Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He previously served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical …See details»
Orchestra BioMed - LinkedIn
Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products ...See details»
Orchestra BioMed Holdings (OBIO) Company Profile & Description
Apr 23, 2025 Orchestra BioMed Holdings, Inc. operates as a biomedical company. The company’s flagship product candidates include Atrioventricular Interval Modulation, a …See details»
Orchestra BioMed Receives FDA Breakthrough Device Designation …
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating …See details»
Our Approach - Orchestra BioMed
Our partnership-enabled business model focuses on forging strategic collaborations with and licensing patented technologies to leading medical device companies to drive successful global commercialization of product candidates …See details»
Orchestra BioMed™ Announces Strategic Collaboration,
Jul 5, 2022 Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences …See details»
Orchestra BioMed (USA) Funding: $282.8M - Medical Startups
Apr 24, 2025 Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address …See details»
Life science R&D management - Orchestra
Plan, manage, and execute R&D programs with Orchestra. Blog. About. Login. Contact us. Navigate the path from discovery to medicine . Plan, manage, and execute R&D programs …See details»
Winning Together in Medtech: Interview with Orchestra BioMed
Orchestra BioMed was born in 2018 in response to this, drawing inspiration from the biotech industry's partnership-driven model. ... The nature of collaboration depends on you and your …See details»
Orchestra BioMed’s Hypertension Device Wins FDA Breakthrough ...
Apr 25, 2025 Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. Medtronic has a commercialization deal with the company …See details»
Orchestra BioMed to Participate in Upcoming Institutional
4 days ago Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading …See details»
Orchestra Biomed Unveils Cardiovascular Treatment Innovation
Apr 22, 2025 Orchestra Biomed has unveiled a revolutionary breakthrough in the treatment of cardiovascular disease. The new technology aims to dramatically enhance patient outcomes in …See details»
Orchestra BioMed receives FDA BDD for AVIM therapy
Apr 22, 2025 Orchestra BioMed announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation, BDD, for atrioventricular interval modulation, AVIM, …See details»
Orchestra BioMed Reports Full Year 2024 Financial Results and …
Dec 31, 2024 NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation …See details»
Orchestra BioMed - Funding, Financials, Valuation & Investors
Orchestra BioMed is a biomedical innovation company that provides high-impact solutions for large unmet needs in procedure-based medicine. New. Resources. ... How much funding has …See details»
Biomedical Innovation News & Events | Orchestra BioMed
New Hope, PA, September 20, 2022 – Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to …See details»
Orchestra BioMed Receives FDA Breakthrough Device ... - BioSpace
Apr 23, 2025 Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships …See details»
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat ... - Nasdaq
4 days ago (RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO), a biomedical company focused on advancing high-impact technologies, announced that the U.S. Food and Drug …See details»